Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity
about
PARP inhibitor treatment in ovarian and breast cancerPARP-1 regulates resistance of pancreatic cancer to TRAIL therapy.Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo.Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis.TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.Role of PARP inhibitors in cancer biology and therapyOxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2Beyond DNA Repair: Additional Functions of PARP-1 in Cancer.Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics.The development of PARP as a successful target for cancer therapy.Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling.Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers.
P2860
Q28741688-78D7CEE9-D20E-4678-BA13-03192041DDF7Q33731141-6CAB2661-83AC-4A6D-BAA0-9E228D4BE689Q34299288-9C771C64-AE4C-4D2A-836C-41C29BA63C02Q34573492-9D792B37-322F-4849-B94F-2C5ACCD87674Q35227104-46B6D72B-C6BD-41EB-9DCD-9EB3A9393E68Q35955457-D366737F-DF1E-4657-A18B-17EF984F947DQ36081375-077410A6-C67C-4901-8106-DC19C271C02BQ36171193-B23060E9-D81C-4700-AD74-C13D89CBC036Q36991056-6EB737C1-5AB9-43F5-B819-3A88A03B3757Q37346306-A87430AB-FBF8-4273-A597-611400BFB7BDQ37727996-67EED809-A7B7-4D01-8704-D954957950DBQ47278103-08363AB0-2745-4C8C-B000-90DAB914B0D6Q48276795-55423A0B-5B1A-4644-AE09-CB870B9A2031Q51487611-20249797-7521-46D9-B25F-B6A27D0AE508
P2860
Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Oral poly(ADP-ribose) polymera ...... preventing acute neurotoxicity
@ast
Oral poly(ADP-ribose) polymera ...... preventing acute neurotoxicity
@en
Oral poly(ADP-ribose) polymera ...... preventing acute neurotoxicity
@nl
type
label
Oral poly(ADP-ribose) polymera ...... preventing acute neurotoxicity
@ast
Oral poly(ADP-ribose) polymera ...... preventing acute neurotoxicity
@en
Oral poly(ADP-ribose) polymera ...... preventing acute neurotoxicity
@nl
prefLabel
Oral poly(ADP-ribose) polymera ...... preventing acute neurotoxicity
@ast
Oral poly(ADP-ribose) polymera ...... preventing acute neurotoxicity
@en
Oral poly(ADP-ribose) polymera ...... preventing acute neurotoxicity
@nl
P2093
P2860
P1476
Oral poly(ADP-ribose) polymera ...... preventing acute neurotoxicity
@en
P2093
Barry M Sherman
James L Abbruzzese
Jianhua Ling
Paul J Chiao
Roberta Rosa
Valeria Ossovskaya
P2860
P304
P356
10.1158/1078-0432.CCR-09-0910
P407
P577
2009-10-06T00:00:00Z